{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:37:31Z","timestamp":1792143451593,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:18:21Z","timestamp":1769775501000},"page":"1073-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3922-3986","authenticated-orcid":false,"given":"Gina Hetland","family":"Brinkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Paulshus","family":"Sundlis\u00e6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Bugge","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Ikdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Birgitte","family":"Aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siri","family":"Lillegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ard.2026.01.003_bib0001","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/art.27592","article-title":"Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons","volume":"62","author":"Graudal","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2026.01.003_bib0002","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/art.21421","article-title":"Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial","volume":"52","author":"Wassenberg","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2026.01.003_bib0003","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.003_bib0004","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/annrheumdis-2013-204788","article-title":"Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial","volume":"73","author":"de Jong","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2013-205143","article-title":"Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial","volume":"74","author":"ter Wee","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.01.003_bib0006","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","article-title":"Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease","volume":"81","author":"Wiebe","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.01.003_bib0007","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.01.003_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.003_bib0009","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.01.003_bib0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.003_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.003_bib0012","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.01.003_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard-2023-224270","article-title":"Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?","volume":"83","author":"van Ouwerkerk","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.003_bib0014","doi-asserted-by":"crossref","first-page":"i4205","DOI":"10.1136\/bmj.i4205","article-title":"Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial","volume":"354","author":"Haavardsholm","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ard.2026.01.003_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/ard-2022-223443","article-title":"Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis","volume":"82","author":"van Ouwerkerk","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.01.003_bib0016","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2021-220403","article-title":"Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies","volume":"80","author":"Maassen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.003_bib0017","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/annrheumdis-2022-222338","article-title":"Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis","volume":"81","author":"van Ouwerkerk","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2Suppl","key":"10.1016\/j.ard.2026.01.003_bib0018","first-page":"S126","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"58","author":"Goekoop-Ruiterman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.01.003_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","article-title":"Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)","volume":"18","author":"Heimans","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.ard.2026.01.003_bib0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2021-220112","article-title":"Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020","volume":"80","author":"Xie","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.003_bib0021","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ard.2025.03.002","volume":"84","author":"Hetland","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.003_bib0022","unstructured":"Forening NR. Metodebok. Available from: https:\/\/metodebok.no\/index.php?action=fag&fag=revma. Last acceessed in October 1, 2025."},{"issue":"8","key":"10.1016\/j.ard.2026.01.003_bib0023","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/annrheumdis-2020-219825","article-title":"Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial","volume":"80","author":"Stouten","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T19:50:55Z","timestamp":1780861855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726000038"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.003","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}